Abstract
Patients with asthma and low levels of type 2 inflammation biomarkers (T2low) have limited effective treatment options and healthcare resource utilization (HCRU) of severe, uncontrolled T2low asthma remains unexplored. We estimated HCRU of T2low and non-T2low patients using real world data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
